COLITIS, ULCERATIVE

This observational study tracks how long patients with moderate-to-severe Crohn's disease or ulcerative colitis continue taking guselkumab, a biologic treatment, in everyday clinical practice. Researchers will measure time until treatment discontinuation and early responses like …

This early-stage trial is testing whether a drug called aletekitug is safe and tolerable for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The drug works by blocking a protein called IL-18, which may play a role in the inflammation that …

This early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital…

This study will measure how much of the drug TREMFYA (guselkumab) passes into breast milk of 10 nursing women who are already taking it for conditions like psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. Researchers will collect milk samples to estimate th…

People with inflammatory bowel disease (Crohn's disease or ulcerative colitis) have a higher risk of developing colorectal cancer. This study follows 800 adults with IBD who need a screening colonoscopy to look for precancerous growths called dysplasia. Researchers aim to underst…

This study looks at medical records from thousands of adults with Crohn's disease or ulcerative colitis treated in Dutch hospitals between 2018 and 2026. Researchers will analyze which treatments patients receive, how often they switch therapies, and how the disease affects other…

This study looks at the viruses (called bacteriophages) living in the guts of people with inflammatory bowel disease (IBD) and healthy people. Researchers want to understand how these viruses differ and whether they can be grown in a lab to create a new treatment. The study invol…